logo

For the Inventor, By the Inventor

Mentor, OH, United States of America

John Joseph Harrington

USPTO Granted Patents = 24 


Average Co-Inventor Count = 2.3

ph-index = 8

Forward Citations = 186(Granted Patents)


Location History:

  • Shaker Heights, OH (US) (1999)
  • Mentor, OH (US) (2002 - 2013)
  • Cleveland, OH (US) (2016)

Company Filing History:

goldMedal12 out of 32 
 
Athersys, Inc.
 patents
silverMedal11 out of 35 
 
Abt Holding Company
 patents
bronzeMedal1 out of 832,912 
Other
 patents

Years Active: 1999-2016

Loading Chart...
Loading Chart...
24 patents (USPTO):Explore Patents
1. 9309262 - [object Object] (2016-04-12),
2. 9284277 - [object Object] (2016-03-15),
3. 8460894 - Calcium-sensing receptor 2 (CaR2) and methods for using (2013-06-11),
4. 8153431 - Compositions and methods for making mutations in cell lines and animals (2012-04-10),
5. 7972853 - Compositions and methods for making mutations in cell lines and animals (2011-07-05),
6. 7842792 - Compositions and methods for non-targeted activation of endogenous genes (2010-11-30),
7. 7785831 - Compositions and methods for non-targeted activation of endogenous genes (2010-08-31),
8. 7767454 - Methods for mutating genes in cells using insertional mutagenesis (2010-08-03),
9. 7569220 - Compositions and methods for non-targeted activation of endogenous genes (2009-08-04),
10. 7420044 - Nucleic acid and protein homologs and uses thereof (2008-09-02),
11. 7419828 - Compositions and methods for non-targeted activation of endogenous genes (2008-09-02),
12. 7316923 - Compositions and methods for non-targeted activation of endogenous genes (2008-01-08),
13. 7033782 - Compositions and methods for non-targeted activation of endogenous genes (2006-04-25),
14. 6897066 - Compositions and methods for non-targeted activation of endogenous genes (2005-05-24),
15. 6740503 - Compositions and methods for non-targeted activation of endogenous genes (2004-05-25),

Title: Innovations by John Joseph Harrington: A Glimpse into His Contributions

Introduction

John Joseph Harrington, based in Mentor, OH, is an accomplished inventor with an impressive portfolio consisting of 23 patents. His work primarily focuses on pharmaceutical compounds and their applications in treating various medical conditions. Harrington's dedication to innovation in the field of therapy continues to make significant impacts.

Latest Patents

Harrington's latest patents involve a series of advanced compounds. One notable invention pertains to thienylindole azepines, which are identified as serotonin receptor (5-HT) ligands. These compounds demonstrate therapeutic potential in treating conditions such as addiction, anxiety, depression, and obesity. Another significant patent discusses benzazepine compounds, also acting as serotonin receptor (5-HT) ligands and proving beneficial for similar disorders. These innovative compositions and their applications highlight Harrington's commitment to enhancing healthcare solutions through his inventions.

Career Highlights

Throughout his career, Harrington has been associated with esteemed companies, notably Athersys, Inc. and Abt Holding Company. His expertise in medicinal chemistry and pharmacology has enabled him to develop compounds that target crucial neurological pathways, providing innovative solutions for various health challenges.

Collaborations

Harrington has collaborated with talented professionals, including Stephen Rundlett and Bruce Sherf. These partnerships have likely facilitated the exchange of ideas and expertise, driving forward their common goal of advancing therapeutic solutions and enhancing patient care through innovative research.

Conclusion

John Joseph Harrington's contributions to pharmaceutical innovations through his numerous patents underscore the importance of research and development in medicine. As he continues to explore new compounds and their therapeutic applications, Harrington remains a vital figure in the realm of scientific invention and innovation. His work stands as a testament to the transformative power of ingenuity in addressing pressing medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…